Advertisement
ALXO vs PBYI
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALXO is a Hold and PBYI is a Hold.
ALXO in +6.78% Uptrend, rising for three consecutive days on October 12, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ALXO advanced for three days, in 214 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALXO's RSI Oscillator exited the oversold zone, 38 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
ALXO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for ALXO moved below the 200-day moving average on October 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALXO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ALXO entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.411) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ALXO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALXO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for PBYI turns positive, indicating new upward trend
PBYI saw its Momentum Indicator move above the 0 level on October 07, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned positive. In 89 of the 96 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PBYI just turned positive on October 09, 2026. Looking at past instances where PBYI's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Following a +3.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBYI advanced for three days, in 259 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Aroon Indicator entered an Uptrend today. In 199 of 227 cases where PBYI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBYI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
PBYI broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PBYI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.659) is normal, around the industry mean (26.782). P/E Ratio (19.275) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (2.105) is also within normal values, averaging (437.542).
ALXO | PBYI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 61 | |
SMR RATING 1..100 | 98 | 44 | |
PRICE GROWTH RATING 1..100 | 94 | 36 | |
P/E GROWTH RATING 1..100 | 100 | 4 | |
SEASONALITY SCORE 1..100 | n/a | 36 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PBYI's Valuation (74) in the Biotechnology industry is in the same range as ALXO (90) in the null industry. This means that PBYI’s stock grew similarly to ALXO’s over the last 12 months.
PBYI's Profit vs Risk Rating (61) in the Biotechnology industry is somewhat better than the same rating for ALXO (100) in the null industry. This means that PBYI’s stock grew somewhat faster than ALXO’s over the last 12 months.
PBYI's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for ALXO (98) in the null industry. This means that PBYI’s stock grew somewhat faster than ALXO’s over the last 12 months.
PBYI's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for ALXO (94) in the null industry. This means that PBYI’s stock grew somewhat faster than ALXO’s over the last 12 months.
PBYI's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for ALXO (100) in the null industry. This means that PBYI’s stock grew significantly faster than ALXO’s over the last 12 months.
| ALXO | PBYI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 84% | N/A |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 72% |
| Momentum ODDS (%) | N/A | 2 days ago 90% |
| MACD ODDS (%) | N/A | 2 days ago 89% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 87% |
| Advances ODDS (%) | 5 days ago 86% | 2 days ago 89% |
| Declines ODDS (%) | 3 days ago 90% | 15 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 67% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALXO’s FA Score shows that 0 FA rating(s) are green while PBYI’s FA Score has 1 green FA rating(s).
- ALXO’s FA Score: 0 green, 5 red.
- PBYI’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALXO’s TA Score shows that 4 TA indicator(s) are bullish while PBYI’s TA Score has 4 bullish TA indicator(s).
- ALXO’s TA Score: 4 bullish, 3 bearish.
- PBYI’s TA Score: 4 bullish, 3 bearish.
Price Growth
ALXO (@Biotechnology) experienced а -15.25% price change this week, while PBYI (@Biotechnology) price change was +5.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.28%. For the same industry, the average monthly price growth was -17.87%, and the average quarterly price growth was -21.14%.
Reported Earning Dates
ALXO is expected to report earnings on Nov 05, 2026.
PBYI is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Biotechnology (-10.28% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALXO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALXO has been loosely correlated with MDGL. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ALXO jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To ALXO | 1D Price Change % | ||
|---|---|---|---|---|
| ALXO | 100% | +11.77% | ||
| MDGL - ALXO | 56% Loosely correlated | -0.04% | ||
| AXON - ALXO | 45% Loosely correlated | +2.15% | ||
| AMRN - ALXO | 43% Loosely correlated | -0.34% | ||
| VERA - ALXO | 36% Loosely correlated | +6.84% | ||
| DCOY - ALXO | 35% Loosely correlated | +5.13% | ||
More | ||||